nach oben

Targeted Oncology

Erschienen in:

01.06.2009 | Review

Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?

verfasst von: Evandro de Azambuja, Philippe L. Bedard, Thomas Suter, Martine Piccart-Gebhart

Erschienen in: Targeted Oncology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Trastuzumab, a monoclonal antibody that blocks HER-2 receptor, improves the survival of women with HER-2-positive early and advanced breast cancer when given with chemotherapy. Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2, is approved for the treatment of metastatic breast cancer patients after failure of prior anthracycline, taxanes and trastuzumab therapies in combination with capecitabine. Importantly, cardiac toxicity, manifested as symptomatic congestive heart failure or asymptomatic left ventricular ejection fraction decline, has been reported in some of the patients receiving these novel anti-HER-2 therapies, particularly when these drugs are used following anthracyclines, whose cardiotoxic potential has been recognized for decades. This review will focus on the incidence, natural history, underlying mechanisms, management, and areas of uncertainty regarding trastuzumab-and lapatinib-induced cardiotoxicity.

Herceptin approved in Japan for early treatment in patients with HER2-positive breast cancer. In Edition 2008

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMed

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed

Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672CrossRefPubMed

Slamon D, Eiermann W, Robert N et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial Phase III comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 100: General Session 2; Abstract 2

Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820CrossRefPubMed

Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215–1221CrossRefPubMed

Perez EA, Koehler M, Byrne J et al (2008) Cardiac safety of lapatinib: pooled analysis of 3, 689 patients enrolled in clinical trials. Mayo Clin Proc 83:679–686CrossRefPubMed

Lee KF, Simon H, Chen H et al (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394–398CrossRefPubMed

10.

Erickson SL, O’Shea KS, Ghaboosi N et al (1997) ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2—and heregulin-deficient mice. Development 124:4999–5011PubMed

11.

Sawyer DB, Zuppinger C, Miller TA et al (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105:1551–1554CrossRefPubMed

12.

Zhao YY, Sawyer DR, Baliga RR et al (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261–10269CrossRefPubMed

13.

Strasser F, Betticher DC, Suter TM (2001) Trastuzumab and breast cancer. N Engl J Med 345:996PubMed

14.

Camenisch TD, Schroeder JA, Bradley J et al (2002) Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 8:850–855PubMed

15.

Crone SA, Zhao YY, Fan L et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459–465CrossRefPubMed

16.

Chien KR (2006) Herceptin and the heart—a molecular modifier of cardiac failure. N Engl J Med 354:789–790CrossRefPubMed

17.

Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13:173–183CrossRefPubMed

18.

Lemmens K, Fransen P, Sys SU et al (2004) Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 109:324–326CrossRefPubMed

19.

Lemmens K, Segers VF, De Keulenaer GW (2005) Letter regarding article by Okoshi et al, neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of {beta}-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation 111:e175 author reply e175CrossRefPubMed

20.

Okoshi K, Nakayama M, Yan X et al (2004) Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation 110:713–717CrossRefPubMed

21.

Lemmens K, Doggen K, De Keulenaer GW (2007) Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116:954–960CrossRefPubMed

22.

Ewer MS, Vooletich MT, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820–7826CrossRefPubMed

23.

Timolati F, Ott D, Pentassuglia L et al (2006) Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41:845–854CrossRefPubMed

24.

Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36CrossRefPubMed

25.

Suter TM, Procter M, van Veldhuisen DJ et al (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859–3865CrossRefPubMed

26.

Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815CrossRefPubMed

27.

Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811–7819CrossRefPubMed

28.

Rastogi P, Jeong J, Geyer CE et al (2007) Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab(H). J Clin Oncol 25:6S LBA513CrossRef

29.

Perez EA, Suman VJ, Davidson NE et al (2008) cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8):1231–1238CrossRefPubMed

30.

Spielman M, Roché H, Humblet Y et al (2007) 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. Breast Cancer Res Treat 106:S19 abstract 72CrossRef

31.

McArthur HL, Chia S (2007) Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 357:94–95CrossRefPubMed

32.

Suter TM, Procter M, Piccart MJ (2008) Trastuzumab-related cardiotoxicty in the herceptin adjuvant trial. J Clin Oncol 26:2053–2054CrossRef

33.

Buzdar AU, Valero V, Ibrahim NK et al (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228–233CrossRefPubMed

34.

Gianni L, Semiglazov V, Manikhas GM et al (2007) Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumor and safety analysis. J Clin Oncol 25:10S abstract 532CrossRef

35.

Gianni L, Eiermann W, Semiglazov V et al (2008) Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Proceedings of the 31st SABCS 2008; LBA 31

36.

Untch M, Rezai M, Loibl S et al (2008) Neoadjuvant treatment of HER2 overexpressingp rimary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophosphamide foloweed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter Intergroup-study “GeparQuattro”. Eur J Cancer 6:47 41LB

37.

Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231–1238CrossRefPubMed

38.

Montemurro F, Faggiuolo R, Redana S et al (2005) Continuation of trastuzumab beyond disease progression. J Clin Oncol 23:2866–2868 discussion 2868–2869CrossRefPubMed

39.

Zuppinger C, Timolati F, Suter TM (2007) Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 7:61–66CrossRefPubMed

40.

Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459–467CrossRefPubMed

41.

Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2902CrossRefPubMed

42.

Burris HA 3rd, Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305–5313CrossRefPubMed

43.

Pandite L, Burris HA, Jones S et al (2004) A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J Clin Oncol 22:238S abstract 3179

44.

Spector NL, Yarden Y, Smith B et al (2007) Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A 104:10607–10612CrossRefPubMed

45.

de Azambuja E, Cardoso F, Meirsman L et al (2008) The new generation of breast cancer clinical trials: the right drug for the right target. Bull Cancer 95:352–357PubMed

46.

Tomasello G, de Azambuja E, Dinh P et al (2008) Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 8:1883–1890CrossRefPubMed

47.

Xia W, Gerard CM, Liu L et al (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24:6213–6221CrossRefPubMed

48.

O’Shaughnessy J, Blackwell KL, Burstein H et al (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26:44S abstract 1015CrossRef

49.

Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332–344CrossRefPubMed

50.

Pegram M, Chan D, Dichmann RA et al (2006) Phase II combined biological therapy targeting the HER-2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100:S28 abstract 301

51.

Perez EA, Romond EH, Suman VJ et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25: abstract 512

Titel: Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
verfasst von: Evandro de Azambuja
Philippe L. Bedard
Thomas Suter
Martine Piccart-Gebhart
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: Targeted Oncology / Ausgabe 2/2009
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-009-0112-2

Springer Medizin

Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

The toxicities of modern targeted therapies—learning from the price of progress

Maximum tolerated dose: clinical endpoint for a bygone era?

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

Renal toxicity of targeted therapies

Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie